23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. Read more…
The award highlights significant company growth and advancement in the field of RNA modifying enzymes (RME) as STORM aims to become the global leader in the field of RME.
Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th […]
RNA epigenetics is an “untapped druggable space” that could be the next breakthrough/ frontier for innovative treatments for cancer and a broad array of other conditions. What is more, is that it lends itself to small molecule drugs adding to the small molecule armamentarium of targeted drugs for cancer that are giving doctors and their […]
